CL2021000481A1 - Inhibidores de sarcómeros cardíacos. - Google Patents

Inhibidores de sarcómeros cardíacos.

Info

Publication number
CL2021000481A1
CL2021000481A1 CL2021000481A CL2021000481A CL2021000481A1 CL 2021000481 A1 CL2021000481 A1 CL 2021000481A1 CL 2021000481 A CL2021000481 A CL 2021000481A CL 2021000481 A CL2021000481 A CL 2021000481A CL 2021000481 A1 CL2021000481 A1 CL 2021000481A1
Authority
CL
Chile
Prior art keywords
cardiac sarcomere
formula
pharmaceutically acceptable
inhibitors
sarcomere inhibitors
Prior art date
Application number
CL2021000481A
Other languages
English (en)
Inventor
Chihyuan Chuang
Bradley P Morgan
Mark Vanderwal
Luke W Ashcraft
Kevin Lau
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CL2021000481A1 publication Critical patent/CL2021000481A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Se proporcionan compuestos de Fórmula (I): Fórmula (I) o una sal farmacéuticamente aceptable de este, donde R1 , R2A, R2B , R 3 , R4 y R5 son tal como se define en la presente. También se proporciona una composición farmacéuticamente aceptable que comprende un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable de este. También se proporcionan métodos para utilizar un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable de este.
CL2021000481A 2018-08-31 2021-02-25 Inhibidores de sarcómeros cardíacos. CL2021000481A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726162P 2018-08-31 2018-08-31

Publications (1)

Publication Number Publication Date
CL2021000481A1 true CL2021000481A1 (es) 2021-07-23

Family

ID=67953902

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000481A CL2021000481A1 (es) 2018-08-31 2021-02-25 Inhibidores de sarcómeros cardíacos.

Country Status (21)

Country Link
US (2) US11414424B2 (es)
EP (1) EP3843842A1 (es)
JP (2) JP7447089B2 (es)
KR (1) KR20210068422A (es)
CN (1) CN112867539A (es)
AR (1) AR116283A1 (es)
AU (1) AU2019328556A1 (es)
BR (1) BR112021003496A2 (es)
CA (1) CA3110237A1 (es)
CL (1) CL2021000481A1 (es)
CO (1) CO2021003115A2 (es)
EA (1) EA202190657A1 (es)
EC (1) ECSP21016009A (es)
IL (1) IL281075A (es)
MA (1) MA53491A (es)
MX (1) MX2021002199A (es)
PH (1) PH12021550400A1 (es)
SG (1) SG11202101769YA (es)
TW (1) TW202023648A (es)
UY (1) UY38358A (es)
WO (1) WO2020047447A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11639351B2 (en) 2018-08-31 2023-05-02 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
WO2022057849A1 (zh) * 2020-09-17 2022-03-24 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
KR20230110538A (ko) * 2020-11-20 2023-07-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도
CA3209557A1 (en) * 2021-03-04 2022-09-09 Bradley P. Morgan Cardiac sarcomere inhibitors
US20230338378A1 (en) 2022-04-26 2023-10-26 MyoKardia, Inc. Methods of Administering Myosin Inhibitors
WO2024050539A1 (en) 2022-09-02 2024-03-07 Cytokinetics, Incorporated Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100595917B1 (ko) 1998-01-26 2006-07-05 웨인 웨스터만 수동 입력 통합 방법 및 장치
AU2002365057A1 (en) * 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
JP4613157B2 (ja) 2003-01-14 2011-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004094424A1 (ja) * 2003-04-21 2004-11-04 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその用途
PL1765327T3 (pl) 2004-06-17 2015-01-30 Cytokinetics Inc Związki, kompozycje i sposoby
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
CN105473576B (zh) * 2013-06-21 2018-10-30 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
MX2022007040A (es) 2015-01-22 2022-06-24 Myokardia Inc Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd).
CN108430997B (zh) 2015-12-17 2021-06-04 先正达参股股份有限公司 杀微生物的噁二唑衍生物
EP3390398A1 (en) 2015-12-18 2018-10-24 Syngenta Participations AG Microbiocidal oxadiazole derivatives
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
PE20211066A1 (es) 2018-08-31 2021-06-09 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos
CN114765954B (zh) 2019-07-17 2024-01-02 赛特凯恩蒂克公司 心脏肌节抑制剂口服制剂
EP3999180B1 (en) 2019-07-17 2024-05-08 Cytokinetics, Inc. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
AU2020378197A1 (en) 2019-11-10 2022-05-26 MyoKardia, Inc. Methods of treatment with myosin modulator
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843A (zh) 2020-11-19 2022-05-20 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
KR20230110538A (ko) 2020-11-20 2023-07-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
WO2022111498A1 (zh) 2020-11-24 2022-06-02 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229A (zh) 2020-11-24 2022-05-27 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CA3209557A1 (en) 2021-03-04 2022-09-09 Bradley P. Morgan Cardiac sarcomere inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11639351B2 (en) 2018-08-31 2023-05-02 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Also Published As

Publication number Publication date
AU2019328556A1 (en) 2021-03-11
AR116283A1 (es) 2021-04-21
BR112021003496A2 (pt) 2021-05-18
ECSP21016009A (es) 2021-05-31
SG11202101769YA (en) 2021-03-30
US20230090256A1 (en) 2023-03-23
MA53491A (fr) 2021-09-15
PH12021550400A1 (en) 2021-12-06
UY38358A (es) 2020-03-31
KR20210068422A (ko) 2021-06-09
US11952381B2 (en) 2024-04-09
MX2021002199A (es) 2021-08-16
JP7447089B2 (ja) 2024-03-11
EP3843842A1 (en) 2021-07-07
CN112867539A (zh) 2021-05-28
JP2021535164A (ja) 2021-12-16
IL281075A (en) 2021-04-29
EA202190657A1 (ru) 2021-07-22
US11414424B2 (en) 2022-08-16
CA3110237A1 (en) 2020-03-05
US20200109148A1 (en) 2020-04-09
JP2024054409A (ja) 2024-04-16
WO2020047447A1 (en) 2020-03-05
CO2021003115A2 (es) 2021-06-10
TW202023648A (zh) 2020-07-01

Similar Documents

Publication Publication Date Title
CL2021000481A1 (es) Inhibidores de sarcómeros cardíacos.
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
PH12017501326A1 (en) Tgf-� inhibitors
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
CL2023002616A1 (es) Inhibidores del sarcómero cardíaco
EA202193015A1 (ru) Ингибиторы cdk
CR20190236A (es) Compuestos terapéuticos y métodos para utilizarlos
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
CL2021002575A1 (es) Compuestos de pirrol
UY39579A (es) COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS
ECSP23089582A (es) Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
CL2021000646A1 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
UY38567A (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
DOP2023000088A (es) Derivados de pirazol como inhibidores de la ret-cinasa
UY38498A (es) Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo
UY38934A (es) Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
EA202192051A1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)
DOP2023000209A (es) Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3
EA202091733A1 (ru) Аналоги дигидробензофурана и индена в качестве ингибиторов саркомера сердца
CO2022006965A2 (es) Inhibidores de egfr
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR116051A1 (es) Derivados de heteroarilo bicíclicos
CO2022012773A2 (es) Moduladores de nampt
MX2021011923A (es) Novedoso derivado de azaindol.